glp-1 colorectal cancer death risk study november 2025 Emerging Evidence Positions Receptor Agonists as a Novel Strategy to Reduce CRC GLP-1 drugs and colorectal cancer

Side effects are similar to injections, but there are some differences

Because of this, they are often used alongside or even before GLP-1 therapies in patients with heart failure or chronic kidney disease

GLP-1 drugs are hardly some experimental medicine

No product was tested by this publication, and no clinical claim made by the brand was independently verified beyond confirming that the brand itself makes the claim

Use is subject to institutional review and applicable regulations

Three primary ionotropic glutamate, NMDA, alpha-amino-3-hydroxy-5-methyl-4-isooxazole-propionate (AMPA), and kainate receptors [92], can trigger excitotoxic cascades